- Poster presentation
- Open Access
Late versus non-late presentation of HIV/AIDS: an economic impact analysis
© Grabmeier-Pfistershammer et al; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Marginal Cost
- Diagnostic Procedure
- Impact Analysis
- Drug Price
- Late Presentation
In Austria up to 25% of newly diagnosed HIV infected patients present with less than 200 CD4 cell/mm3 and/or AIDS (late presenters). Late diagnosis not only adversely affects individual health and survival but may also be associated with higher need for care, thus resulting in higher expenses for the healthcare system.
To assess the marginal costs of late presentation of HIV-infection in Austria.
Direct costs incurred during follow-up, demographic and clinical data were retrospectively collected for all late presenters (=cases) and an age- and risk-group matched cohort of controls (>350 CD4 cells/mm3 and never AIDS at presentation) presenting at the HIV-unit of the Medical University of Vienna between July 2006 and November 2008. Calculation of costs was based on official standard reimbursement systems for in-patient care, out-patient consultations, diagnostic procedures, and drug prices paid by the social insurance company or the hospital.
24 cases and 27 controls were followed over a mean of 15 months. Cases and controls were well matched with regards to age, gender, risk group, migrational background, and follow-up time (p=NS). Median overall costs for late presenters incurred during the observation period were nearly 5 times higher for cases than for controls (21.166 vs. 4.329 Euros; p < 0,05). This difference was driven by higher costs for out-patient consultations (p<0,005), in-patient care (p<0,0001), diagnostic procedures (p< 0,02) and ART (p < 0,005). Costs for non-antiretroviral drugs did not differ significantly between the groups.
Late presentation of HIV-infection is associated with a significant economic burden for the health system during the initial period of care. Higher costs for ART due to the immediate need for treatment account only for part of these costs. Interventions promoting earlier diagnosis of HIV in Austria may therefore prove to be cost-effective.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.